// App-Quantinova.ai

1380 : Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Researchers

Presenter

  • Philippe Moreau

Principal Investigators

  • Mathias Haenel

  • Albert Oriol

  • Paula Rodriguez-Otero

  • Helen McCarthy

  • Kenshi Suzuki

  • Vania T. M. Hungria

  • Anna Sureda Balari

  • Lauriane Clement-Filliatre

  • Cyrille Hulin

  • Hila Magen

  • Shinsuke Iida

  • Vladimir Maisnar

  • Lionel Karlin

  • Ludek Pour

  • Cyrille Touzeau

  • Shiyi Yang

  • Michele Kosh

  • Maria Delioukina

  • Christoph Heuck

  • Hartmut Goldschmidt

Medical Centers

  • Hematology, University Hospital, Nantes, France

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Klinikum Chemnitz, Chemnitz, Germany

  • Institut Catala dOncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

  • The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom

  • Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan

  • Clinica Medica São Germano, São Paulo, Brazil

  • ICO-Hospital Duran i Reynals, LHospitalet de Llobregat, Spain

  • Onco-Hematology, CHU Nancy-Brabois, Vandoeuvre les Nancy, France

  • Department of Hematology, Hospital Haut Leveque, University Hospital Bordeaux, Pessac, France

  • Gastroenterology, Chaim Sheba Medical Center, Ramat-gan & Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan

  • Department of Medicine - Hematology, Charles University Faculty Hospital, Hradec Kralove, Czech Republic

  • Centre Hospitalier Lyon-Sud Hematologie (HCL), Pierre Benite Cedex, France

  • Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

  • Janssen Research and Development, LLC, Spring House, PA

  • Department of Internal Medicine V and National Centre for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

Locations

  • France

  • United States

  • Germany

  • Spain

  • United Kingdom

  • Japan

  • Brazil

  • Israel

  • Czech Republic

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • carfilzomib Intravenous

  • daratumumab Intravenous

  • Bortezomib

  • Prednisone

  • Melphalan

  • Sparsentan

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved